TY - JOUR
T1 - Teaching case
T2 - A man with a progressive gait impairment and visual compromise
AU - Toro, Jaime
AU - Burbano, Lisseth Estefania
AU - Zamora, Adrián
AU - Jones, Erica
N1 - Publisher Copyright:
© 2015 Elsevier B.V. All rights reserved.
PY - 2015/3/1
Y1 - 2015/3/1
N2 - Primary progressive multiple sclerosis can present with a wide variety of symptoms. We report a case of a 52-year-old man presenting with visual symptoms and gait impairment in whom a diagnosis of a primary progressive multiple sclerosis was established. Symptomatic treatment with dalfampridine was started but did not result in a considerable improvement. Gait disorders in multiple sclerosis are common and can have a considerable effect over the patient's quality of life. Dalfampridine is the first drug approved for the symptomatic treatment of gait in MS, although only a 40% of patients show an objective response to this medication. Primary progressive multiple sclerosis represents a therapeutic challenge. Currently, there are no disease modifying treatments approved but there are several medications undergoing assessment for this indication. Further research in the underlying pathophysiology of PPMS will help us develope more successful disease-modifying treatments. Meanwhile, a symptomatic approach should be offered in order to improve the patient's quality of life.
AB - Primary progressive multiple sclerosis can present with a wide variety of symptoms. We report a case of a 52-year-old man presenting with visual symptoms and gait impairment in whom a diagnosis of a primary progressive multiple sclerosis was established. Symptomatic treatment with dalfampridine was started but did not result in a considerable improvement. Gait disorders in multiple sclerosis are common and can have a considerable effect over the patient's quality of life. Dalfampridine is the first drug approved for the symptomatic treatment of gait in MS, although only a 40% of patients show an objective response to this medication. Primary progressive multiple sclerosis represents a therapeutic challenge. Currently, there are no disease modifying treatments approved but there are several medications undergoing assessment for this indication. Further research in the underlying pathophysiology of PPMS will help us develope more successful disease-modifying treatments. Meanwhile, a symptomatic approach should be offered in order to improve the patient's quality of life.
KW - Dalfampridine
KW - Gait disorders
KW - Primary progresive multiple sclerosis
UR - http://www.scopus.com/inward/record.url?scp=84925036139&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84925036139&partnerID=8YFLogxK
U2 - 10.1016/j.msard.2015.02.001
DO - 10.1016/j.msard.2015.02.001
M3 - Article
C2 - 25787194
AN - SCOPUS:84925036139
SN - 2211-0348
VL - 4
SP - 176
EP - 179
JO - Multiple Sclerosis and Related Disorders
JF - Multiple Sclerosis and Related Disorders
IS - 2
ER -